Drug intelligence / Profile preview

SP1002

Development stage: Preclinical
Lead developer: Synchronicity Group
Modality: Small Molecules

Overview

**SP1002** is a preclinical fixed-dose small-molecule combination developed by Synchronicity Group for sleep disturbances and autism-related behaviors in pediatric autism spectrum disorder. It combines tasimelteon, a melatonin receptor MT1 and MT2 agonist intended to support circadian entrainment, with clonidine, an alpha-2 adrenergic receptor agonist that may reduce hyperarousal and support sleep. The program is based on the hypothesis that circadian dysregulation and melatonin deficiency contribute to sleep disturbance in autism spectrum disorder, with subsequent development interest in adult autism spectrum disorder and adolescent attention deficit hyperactivity disorder.

Other names: clonidine + tasimelteontasimelteon + clonidine

Targets

ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)ADRA2B (α2B)ADRA2C (α2C)ADRA2A (α2A)MTNR1A (MT1)MTNR1B (Melatonin Receptor 2)

Beyond the preview

Go deeper on SP1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP1002.